SMMT Summit Therapeutics Inc.

10.57USD+0.67%Mkt Cap: 8.45B USDP/E: —

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate …

Institutional holders20 on file

Key Statistics

Company
Market Cap8.45B USD
Enterprise Value7.79B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.08B USD
Revenue/Share—
Last Price10.57 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees265
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.05
PEG—
EV/EBITDA-9.11
EV/Revenue—
P/S—
P/B14.97
EPS (TTM)-1.06 USD
EPS (Forward)-1.06 USD
52W Range
10.142% of range29.23
52W High29.23 USD
52W Low10.14 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-163.86%
ROA-143.72%
ROIC—
ROCE-161.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-322.93M USD
CapEx (TTM)657.00K USD
FCF Margin—
FCF Yield-2.53%
Net Debt-609.81M USD
Net Debt/EBITDA0.71
Net Debt/FCF—
Balance Sheet
Debt/Equity0.03
Current Ratio5.99
Quick Ratio5.71
Book Value/Sh0.71 USD
Cash/Share0.79 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.94 USD
Upside (mean)+173.8%
Target Range8.219 USD – 42.57 USD
8.219+173.8% to mean42.57
# Analysts13
Ownership
Shares Out.799.76M
Float154.30M
Insiders80.68%
Institutions17.16%
Short Interest
Short Ratio7.6d
Short % Float26.67%
Short % Out.5.28%
Shares Short42.26M
Short (prev mo.)41.16M
Technical
SMA 5016.30 (-35.1%)
SMA 20016.13 (-34.5%)
Beta-1.52
S&P 52W Chg12.08%
Avg Vol (30d)6.20M
Avg Vol (10d)7.15M
Technical Indicators
RSI (14)32.1
MACD-1.1776
MACD Signal-0.5269
MACD Hist.-0.6507
BB Upper19.27 USD
BB Middle14.78 USD
BB Lower10.30 USD
BB Width60.64%
ATR (14)1.285 USD
Vol Ratio (20d)1.40x

About Summit Therapeutics (NASDAQ: SMMT)

›

Summit Therapeutics (NASDAQ: SMMT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 265 employees.

The shares were at 10.57 USD on 19 November 2026, down 41.5% over 52 weeks. Its 52-week range is 10.14 USD to 29.23 USD: the price is 63.8% below the high and 4.2% above the low.

Its market capitalisation is 8.45B USD.

Summit Therapeutics reports return on equity of -163.9% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 609.81M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 28.94 USD is 173.8% above the current price. The next earnings report is expected on 22 February 2027.